Identification of fatty acid amide hydrolase as a metastasis suppressor in breast cancer

Clinical management of breast cancer (BC) metastasis remains an unmet need as it accounts for 90% of BC-associated mortality. Although the luminal subtype, which represents 70% of BC cases, is generally associated with a favorable outcome, it is susceptible to metastatic relapse as late as 15 years...

Descripción completa

Detalles Bibliográficos
Autores: Tundidor, Isabel, Seijo Vila, Marta, Blasco Benito, Sandra, Rubert Hernández, María, Adámez, Sandra, Andradas, Clara, Manzano, Sara, Álvarez López, Isabel, Sarasqueta, Cristina, Villa Morales, María, González Lois, Carmen, Ramírez Medina, Esther, Almoguera, Belén, Sánchez López, Antonio J., Bindila, Laura, Hamann, Sigrid, Arnold, Norbert, Röcken, Christoph, Heras Murillo, Ignacio, Sancho, David, Moreno Bueno, Gema, Caffarel, María M., Guzmán Pastor, Manuel, Sánchez García, María Cristina, Pérez Gómez, Eduardo
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Universidad Complutense de Madrid (UCM)
Repositorio:Docta Complutense
Idioma:inglés
OAI Identifier:oai:docta.ucm.es:20.500.14352/102906
Acceso en línea:https://hdl.handle.net/20.500.14352/102906
Access Level:acceso abierto
Palabra clave:577.1
618.19-006
Bioquímica (Biología)
Oncología
2403 Bioquímica
3201.01 Oncología
Descripción
Sumario:Clinical management of breast cancer (BC) metastasis remains an unmet need as it accounts for 90% of BC-associated mortality. Although the luminal subtype, which represents 70% of BC cases, is generally associated with a favorable outcome, it is susceptible to metastatic relapse as late as 15 years after treatment discontinuation. Seeking therapeutic approaches as well as screening tools to properly identify those patients with a higher risk of recurrence is therefore essential. Here, we report that the lipid-degrading enzyme fatty acid amide hydrolase (FAAH) is a predictor of long-term survival in patients with luminal BC, and that it blocks tumor progression and lung metastasis in cell and mouse models of BC. Together, our findings highlight the potential of FAAH as a biomarker with prognostic value in luminal BC and as a therapeutic target in metastatic disease.

Similares en LA Referencia